RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Biomarin Pharmaceutical Stock

Biomarin Pharmaceutical Stocks 2024

Biomarin Pharmaceutical Stocks

191.6 M

Ticker

BMRN

ISIN

US09061G1013

WKN

924801

In 2024, Biomarin Pharmaceutical had 191.6 M outstanding stocks, a 0% change from the 191.6 M stocks in the previous year.

The Biomarin Pharmaceutical Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e191.6
2028e191.6
2027e191.6
2026e191.6
2025e191.6
2024e191.6
2023191.6
2022189
2021182.9
2020191.7
2019179
2018177.1
2017174.4
2016166
2015160
2014146.3
2013137.8
2012120.3
2011112.1
2010125.7
2009100.3
2008103.6
200795.9
200684.6
200568.8
200464.4

Biomarin Pharmaceutical shares outstanding

The number of shares was Biomarin Pharmaceutical in 2023 — This indicates how many shares 191.595 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Biomarin Pharmaceutical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Biomarin Pharmaceutical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Biomarin Pharmaceutical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Biomarin Pharmaceutical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Biomarin Pharmaceutical Aktienanalyse

What does Biomarin Pharmaceutical do?

Biomarin Pharmaceutical Inc is a biopharmaceutical company that focuses on the development and commercialization of therapies for rare genetic diseases. The company was founded in 1997 and is headquartered in San Rafael, California. Biomarin Pharmaceutical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Biomarin Pharmaceutical revenue by segment

In the annual report of the Biomarin Pharmaceutical share (US09061G1013, 924801, BMRN), it breaks down its revenues into 1 segments: 1. Development & Commercialization of Innovative Therapies. The Biomarin Pharmaceutical stock (WKN: 924801, ISIN: US09061G1013, Ticker Symbol: BMRN) is a leading investment for investors interested in participating in the Health Care sector.

  • 100 % Development & Commercialization of Innovative Therapies

Stocks Details

Evaluating Biomarin Pharmaceutical's Shares Outstanding

Biomarin Pharmaceutical's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Biomarin Pharmaceutical’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Biomarin Pharmaceutical’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Biomarin Pharmaceutical’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Biomarin Pharmaceutical stock

How many stocks are there of Biomarin Pharmaceutical?

The current number of stocks of Biomarin Pharmaceutical is 191.6 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Biomarin Pharmaceutical are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Biomarin Pharmaceutical evolved in recent years?

The number of shares of Biomarin Pharmaceutical has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Biomarin Pharmaceutical as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Biomarin Pharmaceutical?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Biomarin Pharmaceutical pay?

Over the past 12 months, Biomarin Pharmaceutical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Biomarin Pharmaceutical is expected to pay a dividend of 0 USD.

What is the dividend yield of Biomarin Pharmaceutical?

The current dividend yield of Biomarin Pharmaceutical is .

When does Biomarin Pharmaceutical pay dividends?

Biomarin Pharmaceutical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Biomarin Pharmaceutical?

Biomarin Pharmaceutical paid dividends every year for the past 0 years.

What is the dividend of Biomarin Pharmaceutical?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Biomarin Pharmaceutical located?

Biomarin Pharmaceutical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Biomarin Pharmaceutical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Biomarin Pharmaceutical from 9/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/19/2024.

When did Biomarin Pharmaceutical pay the last dividend?

The last dividend was paid out on 9/19/2024.

What was the dividend of Biomarin Pharmaceutical in the year 2023?

In the year 2023, Biomarin Pharmaceutical distributed 0 USD as dividends.

In which currency does Biomarin Pharmaceutical pay out the dividend?

The dividends of Biomarin Pharmaceutical are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Biomarin Pharmaceutical stock can be added to a savings plan with the following providers: Consorsbank

Andere Kennzahlen von Biomarin Pharmaceutical

Our stock analysis for Biomarin Pharmaceutical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biomarin Pharmaceutical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.